紫杉醇加顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床观察

Paclitaxel Plus Cisplatin Combined with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

目的:探讨紫杉醇加顺铂同步放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法:32例患者行常规分割放疗40Gy,针对局部病灶行三维适形放疗(3DCRT)加量至中位总剂量达70Gy/35次。化疗方案为紫杉醇135mg/m2静脉滴注第1天,顺铂20mg/m2静脉滴注,第1天～4天。结果:全组32例均可评价疗效,总有效率(CR+PR)为71.9%。中位缓解期为8.6个月,中位生存期为15.2个月,1年、2年的生存率分别为68.8%和46.9%。主要毒性反应为白细胞减少,Ⅲ度16例(50.0%),Ⅳ度3例(9.7%)。急性放射性肺炎1级～2级13例(40.6%);急性放射性食管炎1级～2级17例(53.1%),3级2例(6.3%)。结论:紫杉醇加顺铂同步放化疗治疗局部晚期NSCLC局控率较高,骨髓毒副反应较明显,急性放射性损伤在大多数患者尚可耐受。

Objective:To evaluate the acute side effects and clinical efficacy of paclitaxel (PTX) plus cisplatin (DDP) combined with concurrent radiotherapy for locally advanced non-small cell lung cancer.Methods: 32 patients with locally advanced NSCLC were given PTX 135mg/m2 by intravenous infusion on day 1, and DDP 20mg/m2 by intravenous infusion on day 1-4. At the same time, they received conventional radiotherapy and 3DCRT to total dose of 70Gy/35f.Results: The response rate(RR) was71.9%.Median TTP was 8.6 months...